Phase II study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia (ALL)

Cancer

Volumn 122, Issue 15, 2016, Pages 2379-2388

  Fathi, Amir T ^a   Deangelo, Daniel J ^b   Stevenson, Kristen E ^b   Kolitz, Jonathan E ^c   Asch, Julie D ^d   Amrein, Philip C ^a   Attar, Eyal C ^a   Steensma, David P ^b   Wadleigh, Martha ^b   Foster, Julia ^a   Connolly, Christine ^a   Galinsky, Ilene ^b   Devoe, Craig E ^c   Stone, Richard M ^b   Neuberg, Donna S ^b   Ballen, Karen K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c North Shore Long Island Center for Advanced Medicine   (United States)

^d Latter Day Saints Hospital   (United States)

Author keywords

Acute lymphoblastic leukemia; Chemotherapy; Older adults; Philadelphia Chromosome; Stem cell transplant

Indexed keywords

ASPARAGINASE MACROGOL; CLOFARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; IMATINIB; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; INDUCTION CHEMOTHERAPY; INFECTION; KIDNEY FAILURE; LIVER TOXICITY; MALE; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; STOMATITIS; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; AGE; ALLOTRANSPLANTATION; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION; SURVIVAL ANALYSIS; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 85051733651     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30037     Document Type: Article

References (44)

1. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012;30: 1663-1669.
2. Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013;31: 1202-1210.
3. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112: 1646-1654.
4. Curran E, Stock W. How I Treat: Acute Lymphoblastic Leukemia in Older Adolescents and Young Adults (AYAs). Blood. 2015;125: 3702-3710.
5. DeAngelo DJ, Stevenson KE, Neuberg DS, et al. A multicenter phase II study using a dose intensified pegylated-asparaginase pediatric regimen in adults with untreated acute lymphoblastic leukemia: A DFCI ALL consortium trial. Blood (ASH Annual Meeting Abstracts). 2015;126: Abstract 80.
6. DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29: 526-534.
7. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64: 9-29.
8. Alvarnas JC, Brown PA, Aoun P, et al. Acute lymphoblastic leukemia. J Natl Compr Canc Netw. 2012;10: 858-914.
9. Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92: 1556-1564.
10. Delannoy A, Sebban C, Cony-Makhoul P, et al. Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients. French Group for Treatment of Adult Acute Lymphoblastic Leukemia. Leukemia. 1997;11: 1429-1434.
11. Goekbuget N, Beck J, Brueggemann M, et al. Moderate intensive chemotherapy including CNSprophylaxis with liposomal cytarabine is feasible and effective in older patients with Phnegative acute lymphoblastic leukemia (ALL): results of a prospective trial from the German Multicenter Study Group for Adult ALL (GMALL). Blood. 2012;120: Abstract 1493.
12. O'Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008;113: 2097-2101.
13. Rowe JM. Optimal management of adults with ALL. Br J Haematol. 2009;144: 468-483.
14. Sancho JM, Ribera JM, Xicoy B, et al. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol. 2007;78: 102-110.
15. Daenen S, van der Holt B, Dekker AW, et al. Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON. Leukemia. 2012;26: 1726-1729.
16. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106: 3760-3767.
17. Burmeister T, Schwartz S, Bartram CR, et al. Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112: 918-919.
18. Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118: 6521-6528.
19. Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109: 3676-3678.
20. Massenkeil G, Nagy M, Neuburger S, et al. Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transplant. 2005;36: 683-689.
21. Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116: 4439-4443.
22. Brissot E, Labopin M, Beckers MM, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100: 392-399.
23. Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011;118: 6043-6049.
24. Huguet F, Leguay T, Raffoux E, et al. Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup. Leuk Lymphoma. 2015;56: 847-857.
25. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21: 4642-4649.
26. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111: 1827-1833.
27. Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008;111: 2563-2572.
28. Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012;157: 463-471.
29. Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010;115: 206-214.
30. Pulte D, Jansen L, Gondos A, et al. Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS One. 2014;9: e85554.
31. Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27: 911-918.
32. Martell MP, Atenafu EG, Minden MD, et al. Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. Br J Haematol. 2013;163: 458-464.
33. Jeha S, Razzouk B, Rytting M, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol. 2009;27: 4392-4397.
34. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102: 2379-2386.
35. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106: 1569-1580.
36. Hurwitz CA, Silverman LB, Schorin MA, et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000;88: 1964-1969.
37. Patel B, Kirkwood A, Dey A, et al. Feasibility of pegylated-asparaginase (PEG-ASP) during induction In adults with acute lymphoblastic leukaemia (ALL): Results from the UK phase 3 multicentre trial UKALL 14. Blood (ASH Annual Meeting Abstracts). 2013;122.
38. Seftel MD, Neuberg D, Zhang MJ, et al. Pediatric-inspired Therapy compared to Allografting for Philadelphia Chromosome Negative Adult ALL in First Complete Remission. Am J Hematol. 2015: [Epub ahead of print].
39. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005;105: 940-947.
40. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006;24: 1917-1923.
41. Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122: 1214-1221.
42. Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16: 57-66.
43. Jain N, O'Brien S, Thomas DA, et al. Inotuzumab ozogamicin in combination with lowintensity chemotherapy (Mini-hyper-CVD) as frontline therapy for older patients (≥60 years) with acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts). 2013;122: 1432.
44. Fathi AT, Borate U, DeAngelo DJ, et al. A phase 1 study of denintuzumab mafodotin (SGNCD19A) in adults with relapsed or refractory B-lineage acute leukemia (B-ALL) and highly aggressive lymphoma. Blood (ASH Annual Meeting Abstracts). 2015;126: Abstract 1328.